The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)
- 190 Downloads
Although gastrointestinal stromal tumor (GIST) is the most frequent mesenchymal neoplasm of the gastrointestinal tract, until recently it has been an obscure disease. Now, there is widespread scientific and clinical interest in GIST because its principal pathogenetic defect has been identified and a specific molecular inhibitor of GIST has been developed. Most GISTs contain a gain-of-function mutation in thec-kit proto-oncogene. Mutation results in constitutive activation of the Kit receptor tyrosine kinase, which induces cellular proliferation. STI571 is an oral agent that selectively inhibits Kit. It is a landmark development in cancer treatment and marks a new era of targeted molecular therapy. Its efficacy proves that a specific inhibitor can counteract the effects of a genetic defect responsible for neoplasia. Althought ST1571 was first applied to GIST only 2 years ago, it has already revolutionized the treatment of patients with metastatic disease and is also currently being tested as an adjuvant therapy after the resection of primary GIST.
Key WordsGastrointestinal stromal tumor GIST c-kit Proto-oncogene STI571
Unable to display preview. Download preview PDF.
- 13.Edmondson J, Marks R, Buckner J, Mahoney M. Contrast of response to D-MAP+sargramostim between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.Proc Am Soc Clin Oncol 1999; 18:541.Google Scholar
- 14.Goss G, Merriam P, Manola J, Singer S, Fletcher C, Demetri G. Clinical and pathological characteristics of gastrointestinal stromal tumors.Proc Am Soc Clin Oncol 2000;19:2203.Google Scholar
- 28.Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the molecularly targeted therapy STI 571 in patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.Proc Am Soc Clin Oncol 2001;20:2. Available at:http://virtualmeeting. asco.org/vm2001/interest_areas/special_sessions/plenary.htm. Accessed: September 3, 2002.Google Scholar
- 44.Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study.Proc Am Soc Clin Oncol 2001;20:2.Google Scholar
- 46.American College of Surgeons Oncology Group. http://www. acosog.org. 2002.Google Scholar